BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 6611419)

  • 1. Critical aspects of the 125I-C1q binding assay for detecting immune complexes in tumor patients.
    Krieger G; Bause I; Kneba M; Kehl A; Nagel GA
    J Clin Lab Immunol; 1984 Jun; 14(2):87-92. PubMed ID: 6611419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-C1q column: ligand specific purification of immune complexes from human serum or plasma. Analysis of the interaction between C1q and immune complexes.
    Kilgallon W; Amlot PL; Williams BD
    Clin Exp Immunol; 1982 Jun; 48(3):705-14. PubMed ID: 6811171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of immune complexes by a microplate-adapted C1q-Protein A enzyme-linked-immunosorbent-assay (C1q-PA-ELISA).
    Bjerrum L; Glikmann G; Jensenius JC; Svehag SE
    J Clin Lab Immunol; 1983 Jan; 10(1):53-8. PubMed ID: 6338238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The complement subcomponent C1q mediates binding of immune complexes and aggregates to endothelial cells in vitro.
    Daha MR; Miltenburg AM; Hiemstra PS; Klar-Mohamad N; Van Es LA; Van Hinsbergh VW
    Eur J Immunol; 1988 May; 18(5):783-7. PubMed ID: 3259929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating immune complexes in Lyme arthritis. Detection by the 125I-C1q binding, C1q solid phase, and Raji cell assays.
    Hardin JA; Walker LC; Steere AC; Trumble TC; Tung KS; Williams RC; Ruddy S; Malawista SE
    J Clin Invest; 1979 Mar; 63(3):468-77. PubMed ID: 429566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 125I-C1q binding activity of soluble antigen-antibody complexes formed in vitro.
    Soltis RD; Hasz DE
    J Clin Lab Immunol; 1982 Nov; 9(2):121-31. PubMed ID: 6984078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C1q-latex assay for immune complexes. Complexes that react with both C1q and monoclonal rheumatoid factor in lupus erythematosus and lung cancer.
    Medof ME
    J Lab Clin Med; 1982 May; 99(5):678-92. PubMed ID: 6978370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding characteristics of three complement dependent assays for the detection of immune complexes in human serum.
    Krieger G; Kneba M; Bolz I; Volling P; Wessels J; Nagel GA
    J Clin Lab Immunol; 1985 Nov; 18(3):129-34. PubMed ID: 3878887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C1q binding activity in the sera of patients with chronic lung diseases.
    Cooper KM; Moore M; Hilton AM
    Clin Exp Immunol; 1981 Jul; 45(1):18-28. PubMed ID: 6975678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of immune complex-like materials in cancer patients' sera: a comparative study of results obtained with the C1q deviation and C1q binding tests.
    Rossen RD; Zubler RH; Day NK; Reisberg MA; Morgan AC; Gutterman JU; Hersh EM
    J Lab Clin Med; 1978 Feb; 91(2):191-204. PubMed ID: 413872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of immune-complex size and antigen-antibody ratio on immune complex detection with monoclonal rheumatoid factor and C1q.
    Vanham G; Bloemmen FJ; Ceuppens JL; Stevens EA
    J Clin Lab Immunol; 1984 Oct; 15(2):63-8. PubMed ID: 6335179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivity of low molecular weight material in cellular immune complex assays.
    Cooper KM; Moore M
    Clin Exp Immunol; 1983 May; 52(2):407-16. PubMed ID: 6602679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Circulating immune complexes: optimization and characteristics of the C1q(I125) fixation test].
    Caillot G; Lamelin JP; Hartmann DJ; Ville G
    Pathol Biol (Paris); 1984 Nov; 32(9):931-7. PubMed ID: 6334270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of immune complexes detectable by two independent assays in gynaecological malignancies.
    Poulton TA; Mooney NA; Nineham LJ; Hay FC
    Clin Exp Immunol; 1983 Sep; 53(3):573-80. PubMed ID: 6604605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Demonstration of circulating immune complexes using a C1q-solid phase enzyme immunoassay].
    Schössler W; Hiepe F; Courault K; Porstmann B; Apostoloff E
    Biomed Biochim Acta; 1983; 42(7-8):1027-35. PubMed ID: 6360166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo degradation of rat C1q induced by intravenous injection of soluble IgG aggregates.
    Veerhuis R; van Es LA; Daha MR
    Immunology; 1985 Apr; 54(4):801-10. PubMed ID: 3872261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A method of isolating C1q from human serum and its use in the solid-phase immunoenzyme determination of immune complexes].
    Belozerov AP
    Lab Delo; 1989; (3):24-6. PubMed ID: 2469833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interaction of human plasma fibronectin with a subunit of the first component of complement, C1q.
    Pearlstein E; Sorvillo J; Gigli I
    J Immunol; 1982 May; 128(5):2036-9. PubMed ID: 6801128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immune complexes in the serum of patients with acute myeloblastic leukemia].
    Späth P; Berchtold P; Engler H; Bütler R
    Schweiz Med Wochenschr; 1984 Oct; 114(40):1373-5. PubMed ID: 6593823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating immune complexes and tumor cell cytotoxins as prognostic indicators in malignant melanoma: a prospective study of 53 patients.
    Rossen RD; Crane MM; Morgan AC; Giannini EH; Giovanella BC; Stehlin JS; Twomey JJ; Hersh EM
    Cancer Res; 1983 Jan; 43(1):422-9. PubMed ID: 6600161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.